Short answer
Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition). New $30M senior secured revolving credit facility with Eclipse Business Capital, maturing March 3, 2029.
Evolus, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New $30M senior secured revolving credit facility with Eclipse Business Capital, maturing March 3, 2029
- Interest rate: SOFR (2.0% floor) + 4.25% margin, with potential downward adjustments based on coverage ratio and availability
- Accordion feature adds up to $10M in additional capacity, subject to lender consent; minimum utilization requirement of $10M
- Prepayment fees punitive early on: 3.0% in year one, 2.0% in year two; limits flexibility to refinance cheaply
- All company assets pledged as collateral; cross-default provisions create risk if other debt obligations are breached
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings results released March 3, 2026: full figures in Exhibit 99.1
- EOLS is a medical aesthetics company (neuromodulator Jeuveau); results reflect competitive botulinum toxin market dynamics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolus, Inc. 8-K filings
Get the next EOLS 8-K as it lands
Follow EOLS for push alerts, or ask the research agent what this filing means.